エピソード

  • Today we dive into three cardiology papers with important insights for cardiac care.

    STUDY #1: We explore an analysis that compares Coronary CT Angiography (CCTA) with stress modalities like SPECT-MPI. We see if CCTA has the potential to reduce the need for invasive angiography, and how it stacks up against other testing strategies.

    Zito, A, Galli, M, Biondi-Zoccai, G, et al. 2023. Diagnostic strategies for the assessment of suspected stable coronary artery disease: A systematic review and meta-analysis. Ann Intern Med. 6: 817–826. (https://www.acpjournals.org/doi/10.7326/M23-0231)

    STUDY #2: We discuss the approval of a dual-chamber leadless pacemaker system by the FDA. Although this study supports the efficacy of this innovative approach in certain scenarios, it also raises important concerns.

    Knops, RE, Reddy, VY, Ip, JE, et al. 2023. A dual-chamber leadless pacemaker. N Engl J Med. 25: 2360–2370. (https://www.nejm.org/doi/10.1056/NEJMoa2300080)

    STUDY #3: We look at a comprehensive retrospective study that evaluates aggressive management of hypertension in hospitalized adults. What are the ramifications of minimizing the use of BP-lowering agents, particularly intravenous ones, in certain inpatient scenarios?

    Anderson, TS, Herzig, SJ, Jing, B, et al. 2023. Clinical outcomes of intensive inpatient blood pressure management in hospitalized older adults. JAMA Intern Med. 7: 715–723. (https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2805021)

    Join us as we dissect these studies, unpacking their methodologies, outcomes, and the intriguing questions they raise.

    For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast

    Learn more with these courses:

    Pacemaker Essentials: https://www.medmastery.com/courses/pacemaker-essentials

    Pacemaker Essentials Workshop: https://www.medmastery.com/workshops/pacemaker-essentials-workshop

    Coronary Angiography Essentials: https://www.medmastery.com/courses/coronary-angiography-essentials

  • In our latest episode, we venture into the heart of cardiology innovation, exploring groundbreaking studies that are reshaping how we approach common cardiovascular conditions.

    STUDY #1: Our journey begins with a Lancet paper that looks at a potential alternative for treating supraventricular tachycardias (SVTs). Imagine a world where the distress of SVTs can be alleviated without ablation, a rush to the emergency department or the complexities of intravenous therapy. An intranasal medication might be the key, offering a beacon of hope for patients seeking simpler, yet effective solutions. But how effective is this approach, and what does it mean for the future of SVT management?

    Stambler, BS, Camm, AJ, Alings, M, et al. 2023. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): A multicentre, randomized trial. Lancet. 10396: 118–128. (https://doi.org/10.1016/S0140-6736(23)00776-6)

    STUDY #2: Transitioning to the realm of antiplatelet therapy, we confront the longstanding question of P2Y12 inhibitors versus aspirin. Will these new findings tilt the balance and shift our approach to secondary coronary prevention? The nuances of this study prompt a deeper reflection on patient-centric care and the economics of new-generation medications.

    Gragnano, F, Cao, D, Pirondini, L, et al. 2023. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2: 89–105. (https://doi.org/10.1016/j.jacc.2023.04.051)

    STUDY #3: Lastly, we explore the potential of bempedoic acid in the landscape of cholesterol management, particularly for patients who are intolerant to statins. With cardiovascular diseases looming as a pervasive threat, the quest for alternative treatments is critical. We see if bempedoic acid could play a potential role in reducing major cardiovascular events, either alongside, or perhaps in lieu of, traditional statin therapy.

    Nissen, SE, Menon, V, Nicholls, SJ, et al. 2023. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2: 131–140. (https://doi.org/10.1001/jama.2023.9696)

    Kazi, DS. 2023. Bempedoic acid for high-risk primary prevention of cardiovascular disease: Not a statin substitute but a good plan B. JAMA. 2: 123–125. (https://doi.org/10.1001/jama.2023.9854)

    Each study we discuss brings its own set of questions, implications, and possibilities for the future of cardiology. From the practicalities of new drug administrations to the cost and effectiveness of established therapies, this episode will get you up to speed!

    For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • エピソードを見逃しましたか?

    フィードを更新するにはここをクリックしてください。

  • Our latest episode dissects three groundbreaking studies that are reshaping our understanding of the heart and its intricate connections to the body and mind.

    STUDY #1: First, we explore the potential of high-sensitivity cardiac troponin I (hs-cTnI) in risk-stratifying patients with known coronary artery disease. While current guidelines don't yet recommend these tests, could there be untapped value in using troponin concentration as a preventive treatment guide? Join us as we explore the intriguing possibilities and implications presented in this study from the Journal of the American College of Cardiology.

    Wereski, R, Adamson, P, Daud, NSS, et al. 2023. High-sensitivity cardiac troponin for risk assessment in patients with chronic coronary artery disease. J Am Coll Cardiol. 6: 473–485. (https://doi.org/10.1016/j.jacc.2023.05.046)

    STUDY #2: Next, we shift our focus to the brain-heart connection. Ever wondered about the cognitive repercussions of a myocardial infarction (MI)? This study from JAMA Neurology sheds light on the potential cognitive consequences of an MI.

    Johansen, MC, Ye, W, Gross, A, et al. 2023. Association between acute myocardial infarction and cognition. JAMA Neurol. 7: 723–731. (https://doi.org/10.1001/jamaneurol.2023.1331)

    STUDY #3: Third, we dive deep (pun intended!) into decompression illness. Certain divers might want to reconsider their next dive because a recent Annals of Internal Medicine study suggests a primary mechanism behind decompression illness that could change the way we perceive diving risks. What are the implications for those passionate about the deep blue?

    Lee, H-J, Lim, DS, Lee, J, et al. 2023. Decompression illness in divers with or without patent foramen ovale: A cohort study. Ann Intern Med. 7: 934–939. (https://doi.org/10.7326/M23-0260)

    Don't miss out on these captivating discussions. Listen in to stay at the forefront of cardiology insights and to satiate your curiosity about these studies' findings. We promise, it's a heartbeat away from being your favorite episode yet!

    For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • Our latest episode of Cardiology Digest delves into some of the most intriguing and thought-provoking recent studies in the realm of heart health. Here's a sneak peek into what awaits you:

    STUDY #1: We have the Amiodarone Enigma: An observational study in the Annals of Internal Medicine has brought up some concerns regarding the use of amiodarone in patients with heart failure, coronary disease, and renal failure. But is everything as it seems? Dive into the nuances of this study with us, as we explore whether the observed excess bleeding is truly due to the drug, or the elevated bleeding risk in these patients. Is it time to change our practice or do we need more compelling evidence?

    Ray WA et al. Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: A retrospective cohort study. Ann Intern Med 2023 Jun; 176:769. (https://doi.org/10.7326/M22-3238)

    STUDY #2: We re-evaluate Aspirin for older patients, thanks to the ASPREE study that was recently published in JAMA Network Open. It looks like it’s time to reassess our recommendations and consider whether we’re truly informed about the pros and cons of aspirin as a risk-reduction strategy.

    Cloud GC et al. Low-dose aspirin and the risk of stroke and intracerebral bleeding in healthy older people: Secondary analysis of a randomized clinical trial. JAMA Netw Open 2023 Jul 3; 6:e2325803. (https://doi.org/10.1001/jamanetworkopen.2023.25803)

    STUDY #3: Lastly, we find out if there are health benefits to being a “weekend warrior”. Have you ever had patients question the health benefits of their active weekends? This study from JAMA sheds light on the potential importance of exceeding the 150-minute weekly threshold of moderate-to-vigorous physical activity. But just how beneficial is it? Tune in to find out!

    Khurshid S et al. Accelerometer-derived “weekend warrior” physical activity and incident cardiovascular disease. JAMA 2023 Jul 18; 330:247. (https://doi.org/10.1001/jama.2023.10875)

    Join us in this episode as we dissect these studies, offering insights and sparking discussions that could reshape our understanding of cardiology. Don't miss out on this enlightening journey!

    For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • Welcome to the latest episode of Cardiology Digest, where we dive into the pressing questions of today's medical research. Here's a glimpse of what's to come:

    STUDY #1: Have you ever wondered about the optimal timing for introducing DOACs (direct-acting oral anticoagulants) after strokes due to atrial fibrillation? This New England Journal of Medicine study dives into the potential advantages of early DOAC introduction. You might be surprised at the rates of symptomatic intracranial hemorrhage. But remember, patient profiles vary—for example, what works for those with mild neurologic deficits might not hold true for everyone.

    Fischer, U, Koga, M, Strbian, D, et al. 2023. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med. 26: 2411–2421. (https://doi.org/10.1056/NEJMoa2303048)

    STUDY #2: Next, we’ll take a look at the curious case of rising hematocrit in certain chronic kidney disease patients who have anemia and were treated with SGLT-2 inhibitors. Did they have a genuine improvement in anemia or was it merely an illusion? SGLT-2 inhibitors are the focal point, and we'll dissect their multifaceted effects that may be at play here.

    Koshino, A, Schechter, M, Chertow, GM, et al. 2023. Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid. 6. (https://doi.org/10.1056/EVIDoa2300049)

    STUDY #3: Hospitalization due to COVID-19 has presented a conundrum regarding post-discharge thromboprophylaxis. With the pandemic making such profound impacts on global health, it's crucial to address these concerns. See how new findings align with prior observational studies, and where rivaroxaban fits into all of this.

    Wang, TY, Wahed, AS, Morris, A, et al. 2023. Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization. Ann Intern Med. 4: 515–523. (https://doi.org/10.7326/M22-3350)

    STUDY #4: Cholesterol management remains pivotal in cardiac care. But the question our fourth study poses is this: do age differences impact the effectiveness of statins, particularly in lowering LDL cholesterol? A dive into this study could reshape perceptions on dosage recommendations for certain patient demographics.

    Corn, G, Melbye, M, Hlatky, MA, et al. 2023. Association between age and low-density lipoprotein cholesterol response to statins: A Danish nationwide cohort study. Ann Intern Med. 8: 1017–1026. (https://doi.org/10.7326/M22-2643)

    So, arm yourself with your favorite beverage and comfy earphones, and join us in uncovering the gems these studies hold. The revelations might just change the way you see these medications and treatments! 🎧🔍📚

    For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • Welcome to the latest episode of Medmastery’s Cardiology Digest, where we keep you up-to-date in the ever-evolving world of cardiology. This episode promises to be a riveting exploration of breakthrough studies!

    STUDY #1: First, we'll delve into a national registry study on transcatheter mitral valve repair in a population that’s different from what the approval was initially based upon. We'll discuss the study's implications, as we eagerly await additional trials comparing this method to traditional surgery.

    Makkar, RR, Chikwe, J, Chakravarty, T, et al. 2023. Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA. 20: 1778–1788. (https://doi.org/10.1001/jama.2023.7089)

    STUDY #2: Next, we turn our attention to a ground-breaking study examining a standardized periprocedural management strategy using direct-acting oral anticoagulants for patients undergoing endoscopy. Given the study's complication rates and length of the anticoagulant interruption period, this novel approach may redefine standards for patients with atrial fibrillation.

    Hansen-Barkun, C, Martel, M, Douketis, J, et al. 2023. Periprocedural management of patients with atrial fibrillation receiving a direct oral anticoagulant undergoing a digestive endoscopy. Am J Gastroenterol. 5: 812–819. (https://doi.org/10.14309/ajg.0000000000002076)

    STUDY #3: Our third study puts the spotlight on the challenging mission to enhance the success rate for paroxysmal atrial fibrillation treatment. We'll explore whether wider-area ablation proved superior to standard ablation for reducing recurrence, contrast that to previous trials, and touch on what’s most important when considering the reasoning behind the choice of wider-area ablation versus standard ablation.

    Nair, GM, Birnie, DH, Nery, PB, et al. 2023. Standard vs augmented ablation of paroxysmal atrial fibrillation for reduction of atrial fibrillation recurrence: The AWARE randomized clinical trial. JAMA Cardiol. 5: 475–483. (https://doi.org/10.1001/jamacardio.2023.0212)

    STUDY #4: Lastly, we dissect a study centered on epicardial ablation for patients with Brugada syndrome who are suffering from ventricular fibrillation. Could this burgeoning therapy eventually replace the current implantable cardioverter–defibrillator approach?

    Nademanee K et al. Long-term outcomes of Brugada substrate ablation: A report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry). Circulation 2023 Mar 24; [e-pub]. (https://doi.org/10.1161/CIRCULATIONAHA.122.063367)

    Join us as we unravel the complexities and potential game-changers these studies offer, and embark on a journey to better understand the future landscape of cardiology. Tune in and learn with Medmastery’s Cardiology Digest!

    For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • Welcome to another episode of Medmastery’s Cardiology Digest! Today, we're diving into three fascinating studies that have stirred up a bit of chatter in the medical world. So grab your coffee and let's delve right in!

    STUDY #1: First, we dig into a study that issues a wake-up call about the potential accuracy of home blood pressure measurements. A dash of detective work is required here that could be the key to solving the mystery of some blood pressure anomalies. Cue suspenseful music!

    Picone DS et al. Availability, cost, and consumer ratings of popular nonvalidated vs validated blood pressure–measuring devices sold online in 10 countries. JAMA 2023 May 2; 329:1514. (https://doi.org/10.1001/jama.2023.2661)

    STUDY #2: Our second study takes a close look at 24-hour ambulatory blood pressure measurement and its prognostic value. It’s a robust study, but doesn't shy away from addressing some thorny issues surrounding the use of ambulatory monitoring in the U.S. Does this comprehensive blood pressure monitoring lead to better clinical outcomes? This is sure to spark some debate!

    Staplin N et al. Relationship between clinic and ambulatory blood pressure and mortality: An observational cohort study in 59 124 patients. Lancet 2023 May 5; [e-pub]. (https://doi.org/10.1016/S0140-6736(23)00733-X)

    STUDY #3: Lastly, we explore a paper that evaluates whether apixaban, a commonly prescribed oral anticoagulant, had a higher rate of thromboembolic events than warfarin when given to patients with On-X mechanical aortic valves. Tune in as we explore the implications of this eye-opening research!.

    Wang TY et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid 2023 May 6; [e-pub]. (https://doi.org/10.1056/EVIDoa2300067)

    Join us for this informative overview of contemporary research, as we break down complex medical concepts into digestible nuggets of knowledge, suitable for both medical students and healthcare professionals eager to keep up-to-date in cardiology.

    For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • Welcome to another enlightening episode of our podcast, where we delve into the latest medical research to bring you insights that can enhance your understanding and practice. This episode focuses on four intriguing studies:

    STUDY #1: We begin with a fascinating study comparing the responses of an AI chatbot and physicians to medical questions posted on a Reddit forum. The results might surprise you and prompt a rethink on how AI can assist in routine physician duties.

    Ayers JW et al. Comparing physician and artificial intelligence chatbot responses to patient questions posted to a public social media forum. JAMA Intern Med 2023 Apr 28; [e-pub]. (https://doi.org/10.1001/jamainternmed.2023.1838)

    STUDY #2: Next, we delve into the POISE-3 trial, which examined the effects of hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery. The findings could have significant implications for the management of patients with hypertension undergoing surgery.

    Marcucci M et al. Hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery: An international randomized controlled trial. Ann Intern Med 2023 Apr 25; 176:605. (https://doi.org/10.7326/M22-3157)

    STUDY #3: Our third study is the IRONMAN trial, which investigated the effects of intravenous ferric derisomaltose in patients with heart failure and iron deficiency. The results provide further support for the benefit of iron repletion in this population.

    Kalra PR et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022 Dec 17; 400:2199. (https://doi.org/10.1016/S0140-6736(22)02083-9)

    STUDY #4: Finally, we discuss a subgroup analysis of the AFFIRM-AHF trial, exploring the association between hemoglobin levels and the efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency. The findings shed light on the role of hemoglobin levels in the treatment outcomes of these patients.

    Filippatos G et al. Association between hemoglobin levels and efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency: An AFFIRM-AHF subgroup analysis. Circulation 2023 Apr 13; [e-pub]. (https://doi.org/10.1161/CIRCULATIONAHA.122.060757)

    This episode promises to be a treasure trove of knowledge, offering insights into the role of AI in medicine, the management of hypertension in surgery, the importance of iron repletion in heart failure, and the influence of hemoglobin levels on treatment outcomes. So, grab your headphones and join us as we navigate these captivating studies. Don't miss this opportunity to enhance your understanding and make a difference in patients' lives. See you there!

    For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • Welcome to Episode 3 of Medmastery's Cardiology Digest, where we bring you expert insights and the latest scientific findings in the field of cardiology. Stay updated with our bite-sized summaries of late-breaking trials. Hit the subscribe button so you never miss an important update again.

    In today's episode, we'll discuss four studies that shed light on new developments in cardiology and medicine:

    STUDY 1: The final 15-month results of the MASTER-DAPT trial by Landi A et al. show that abbreviated antiplatelet therapy is non-inferior to standard antiplatelet therapy for high bleeding risk patients undergoing percutaneous coronary intervention (PCI). The trial found that abbreviated therapy significantly reduced the risk of bleeding, with no increase in the risk of ischemic events.

    Landi A et al. Abbreviated or standard antiplatelet therapy in HBR patients: Final 15-month results of the MASTER-DAPT trial. JACC Cardiovasc Interv 2023 Apr 10; 16:798. (https://doi.org/10.1016/j.jcin.2023.01.366)

    STUDY 2: The prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players is discussed in a recent study by Bhatia RT et al. The study found that over 20% of the players had de-novo ECG changes, which were associated with myocardial inflammation and fibrosis. The authors recommend routine ECG screening for athletes post-COVID-19 infection.

    Bhatia RT et al. Prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players. Heart 2023 Mar 27; [e-pub]. (https://doi.org/10.1136/heartjnl-2022-322211)

    STUDY 3: Haupt CE and Marks M discuss the benefits, limits, and risks of AI-generated medical advice in their recent JAMA article. They argue that AI-generated advice has the potential to improve clinical decision-making and reduce errors, but highlight the need for appropriate training, validation, and regulation to ensure patient safety.

    Haupt CE, Marks M. AI-Generated Medical Advice-GPT and Beyond. JAMA. 2023 Apr 25;329(16):1349-1350. doi: 10.1001/jama.2023.5321. PMID: 36972070.

    Study 4: Lee P et al. discuss the benefits, limits, and risks of GPT-4 as an AI chatbot for medicine in their recent NEJM article. They note that while GPT-4 has the potential to improve patient education and communication, it also raises concerns around privacy, liability, and bias. The authors highlight the need for further research and guidelines on the use of AI chatbots in healthcare.

    Lee P, Bubeck S, Petro J. Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine. N Engl J Med. 2023 Mar 30;388(13):1233-1239. doi: 10.1056/NEJMsr2214184. PMID: 36988602.

    Thanks for listening to Medmastery's Cardiology Digest. Join us next week for more expert insights and scientific updates and visit https://www.medmastery.com/podcasts/cardiology-podcast for more information.

  • We've got an amazing podcast episode lined up for you that'll surely quench your thirst for knowledge on cardiovascular health.

    In this episode, we dive deep into four intriguing studies:

    STUDY #1: First, we'll explore how the Mediterranean diet can work wonders for your heart, and how a simple low-fat diet may offer similar benefits. Can both diets really reduce mortality in patients at increased risk? Tune in to find out!

    Karam G et al. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: Systematic review and network meta-analysis. BMJ 2023 Mar 29; 380:e072003. (https://doi.org/10.1136/bmj-2022-072003)

    STUDY #2: Next, we'll unravel the mystery behind the low statin use for primary prevention of ASCVD among all race and ethnicity groups, with Black and Hispanic adults being the least likely to receive them. Why is this happening, and what can we do about it? 💊

    Jacobs JA et al. Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol 2023 Mar 22; [e-pub]. (https://doi.org/10.1001/jamacardio.2023.0228)

    STUDY #3: Third, we'll talk about a meta-analysis that redefines which patients benefit from CRT and which don't. Brace yourself for some practice-changing revelations as we discuss LBBB, IVCD, and the magic number: 150 ms QRS duration. ⚡

    Friedman DJ et al. Cardiac resynchronization therapy improves outcomes in patients with intraventricular conduction delay but not right bundle branch block: A patient-level meta-analysis of randomized controlled trials. Circulation 2023 Mar 7; 147:812. (https://doi.org/10.1161/CIRCULATIONAHA.122.062124)

    STUDY #4: Lastly, we'll touch on the alarming decline in U.S. life expectancy, especially for young and middle-aged adults. Heart disease is on the rise, and it's high time we focus on preventing cardiovascular disease (CVD) early in life. 🚨

    Aggarwal R et al. Cardiovascular risk factor prevalence, treatment, and control in US Adults aged 20 to 44 years, 2009 to Mar 2020. JAMA 2023 Mar 5; [e-pub]. (https://doi.org/10.1001/jama.2023.2307)

    This episode is a treasure trove of knowledge and insights into cardiovascular health. So grab your headphones and get ready to be enlightened! Join us as we navigate these captivating studies and uncover the secrets to a healthier heart. Don't miss this opportunity to enhance your understanding and make a difference in patients' lives. See you there!

    For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

  • Welcome to another exciting podcast episode, where we dive into the latest cardiovascular research!

    Join us as we discuss four fascinating studies:

    STUDY #1: Discover how subclinical coronary atherosclerosis detected by computed tomographic angiography (CTA) can pose a significant risk for myocardial infarction (MI) in asymptomatic middle-aged men and women in a Danish cohort.

    Fuchs A et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort: A prospective observational cohort study. Ann Intern Med 2023 Mar 28; [e-pub]. (https://doi.org/10.7326/M22-3027)

    STUDY #2: We'll examine the Open Payments Program (OPP) data, revealing trends in industry payments to cardiologists from 2014 to 2019, including the necessity for transparency.

    Zhang R et al. Trends in industry payments to cardiologists from 2014 to 2019. Circ Cardiovasc Qual Outcomes 2023 Mar 17; [e-pub]. (https://doi.org/10.1161/CIRCOUTCOMES.122.009820)

    STUDY #3: In this randomized case-crossover study, we'll explore whether caffeinated coffee affects premature atrial contractions (PACs) and ventricular contractions (PVCs) in healthy adults.

    Marcus GM et al. Acute effects of coffee consumption on health among ambulatory adults. N Engl J Med 2023 Mar 23; 388:1092. (https://doi.org/10.1056/NEJMoa2204737)

    STUDY #4: Lastly, we'll discuss a phase 3 trial of sotatercept, a potential new class of therapy for pulmonary arterial hypertension (PAH), focusing on its effects on 6-minute walk distance and other secondary endpoints.

    Hoeper MM et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023 Mar 6; [e-pub]. (https://doi.org/10.1056/NEJMoa2213558)

    This episode promises to be a wealth of knowledge and insights into cardiovascular health. So, get comfortable, grab your headphones, and let's dive into these captivating studies to uncover the secrets to a healthier heart. Enhance your understanding and make a difference in patients' lives. See you there!

    For shownotes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.